Mostrar el registro sencillo del ítem

dc.contributor.authorPuertas Neyra, Kevin Louis
dc.contributor.authorCoco Martín, Rosa María 
dc.contributor.authorHernández Rodríguez, Leticia A
dc.contributor.authorGobelli, Dino Joaquin 
dc.contributor.authorGarcía Ferrer, Yenisey
dc.contributor.authorPalma Vecino, Raicel
dc.contributor.authorTellería Orriols, Juan José 
dc.contributor.authorSimarro Grande, María 
dc.contributor.authorFuente García, Miguel Ángel de la 
dc.contributor.authorFernández Bueno, Iván 
dc.date.accessioned2024-07-22T19:25:46Z
dc.date.available2024-07-22T19:25:46Z
dc.date.issued2024-07-02
dc.identifier.citationStem Cell Res Ther. 2 Jul 2024, vol. 15, n. 1, Article number: 192, 24 páginas.es
dc.identifier.issn1757-6512es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/68995
dc.descriptionProducción Científicaes
dc.description.abstractABSTRACT. BACKGROUND: Inherited retinal dystrophies (IRD) are one of the main causes of incurable blindness worldwide. IRD are caused by mutations in genes that encode essential proteins for the retina, leading to photoreceptor degeneration and loss of visual function. IRD generates an enormous global financial burden due to the lack of understanding of a significant part of its pathophysiology, molecular diagnosis, and the near absence of non-palliative treatment options. Patient-derived induced pluripotent stem cells (iPSC) for IRD seem to be an excellent option for addressing these questions, serving as exceptional tools for in-depth studies of IRD pathophysiology and testing new therapeutic approaches. METHODS: From a cohort of 8 patients with PROM1-related IRD, we identified 3 patients carrying the same variant (c.1354dupT) but expressing three different IRD phenotypes: Cone and rod dystrophy (CORD), Retinitis pigmentosa (RP), and Stargardt disease type 4 (STGD4). These three target patients, along with one healthy relative from each, underwent comprehensive ophthalmic examinations and their genetic panel study was expanded through clinical exome sequencing (CES). Subsequently, non-integrative patient-derived iPSC were generated and fully characterized. Correction of the c.1354dupT mutation was performed using CRISPR/Cas9, and the genetic restoration of the PROM1 gene was confirmed through flow cytometry and western blotting in the patient-derived iPSC lines. RESULTS: CES revealed that 2 target patients with the c.1354dupT mutation presented monoallelic variants in genes associated with the complement system or photoreceptor differentiation and peroxisome biogenesis disorders, respectively. The pluripotency and functionality of the patient-derived iPSC lines were confirmed, and the correction of the target mutation fully restored the capability of encoding Prominin-1 (CD133) in the genetically repaired patient-derived iPSC lines. CONCLUSIONS: The c.1354dupT mutation in the PROM1 gene is associated to three distinct AR phenotypes of IRD. This pleotropic effect might be related to the influence of monoallelic variants in other genes associated with retinal dystrophies. However, further evidence needs to be provided. Future experiments should include gene-edited patient-derived iPSC due to its potential as disease modelling tools to elucidate this matter in question.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherBMC Part of Springer Naturees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.classificationiPSC, Retinal diseases, PROM1 gene, CD133, Retinitis pigmentosa, Cone-rod dystrophy, Stargardt’s type 4 diseasees
dc.titleClinical exome analysis and targeted gene repair of the c.1354dupT variant in iPSC lines from patients with PROM1-related retinopathies exhibiting diverse phenotypeses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holderBMC Part of Springer Naturees
dc.identifier.doi10.1186/s13287-024-03804-2es
dc.relation.publisherversionhttps://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03804-2es
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue1es
dc.identifier.publicationlastpage24es
dc.identifier.publicationtitleStem Cell Research & Therapyes
dc.identifier.publicationvolume15es
dc.peerreviewedSIes
dc.description.projectThe study was funded by grant PID2020-118860RB-100 and PID2020-118517RB-I00 funded by MCIN/AEI/https://doi. org/10.13039/501100011033. Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485). Consejería de Educación, Junta de Castilla y León (VA172P20). Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León. Kevin Puertas-Neyra was funded by predoctoral contracts UVa2020 (co-funded by Santander Bank) and Junta de Castilla y Leon 2021.es
dc.identifier.essn1757-6512es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.09 Oftalmologíaes


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem